Not from impression — from three disciplined, source-traced evidence bases.不靠印象 —— 建立在三个严谨、可溯源的证据基础上。
Market sizing and growth triangulated across Grand View Research, Mordor Intelligence and SNS Insider — figures shown as ranges, with each source's scope noted.市场规模与增长，交叉验证自 Grand View Research、Mordor Intelligence 与 SNS Insider —— 数字以区间呈现，并标注各来源的口径。
The two most active longevity advertisers in the Klang Valley, read from the Meta Ad Library and verbatim video transcripts. Snapshot dated 2026-07-02.巴生谷最活跃的两家长寿医学投广诊所，取自 Meta 广告库 与逐字视频转录。数据快照日期 2026-07-02。
NPRA CGTP Second Edition, MOH/MMC advertising guidelines and Meta's health-ad policy, reviewed against primary sources.NPRA CGTP 第二版、MOH/MMC 广告指南与 Meta 健康广告政策，对照一手来源查阅。
* This report is market & competitive intelligence. It makes no clinical claims; technology is discussed solely as marketing positioning. Not clinical guidance.* 本报告为市场与竞争情报，不作任何临床声明；技术仅以营销定位的角度讨论。非临床指导。
Fewer than five clinics nationally lead with a dedicated longevity identity. Two advertisers dominate the Klang Valley conversation — and they split the field cleanly by language and model.全国以「专注长寿医学」为主要身份的诊所不到五家。两家投广诊所主导巴生谷的讨论 —— 而他们按语言与模式清晰地一分为二。
| Advertiser投广诊所 | Model模式 | Active ads在投广告 | Language语言 | Price posture价格姿态 | CTA |
|---|---|---|---|---|---|
| Nadi Clinic / Nadi MediPJ · Aesthetic × Regenerative × Longevity hybrid · 10,033 FB likesPJ · 医美 × 再生 × 长寿 混合 · 10,033 FB 粉丝 | Hybrid混合型 | 61 | CN · EN · BM | Transparent (P-SHOT RM 2,800–3,800 shown in ads)透明（P-SHOT RM 2,800–3,800 于广告标示） | |
| Longevity Clinic AsiaKL · Dedicated longevity / functional medicine · "Malaysia's First," IFM-certifiedKL · 专注长寿 / 功能医学 · 「Malaysia's First」，IFM 认证 | Dedicated专注型 | 22 | EN ~80% · CN | No public price — consultation-gated不公开价格 —— 需咨询 | Website consult官网咨询 |
* "Active ads" = ads running at snapshot on the Meta Ad Library, public data, 2026-07-02. Both figures are public-data counts, not spend. Longevity Clinic Asia's international patient roster includes the UK, Canada, Sweden, France, Iran, Greece and Nigeria (per its ad copy); it holds Malaysia Book of Records + Aijian Records 2025 recognition.* 「在投广告」= 2026-07-02 于 Meta 广告库快照时在投的广告，公开数据。两个数字均为公开计数，非投放金额。Longevity Clinic Asia 的国际患者名单（据其广告文案）涵盖英国、加拿大、瑞典、法国、伊朗、希腊与尼日利亚；并持有 Malaysia Book of Records + 大马纪录 2025 认可。
Read verbatim from downloaded video transcripts. Two very different playbooks — one built on relatable symptom-and-shame, the other on philosophy-and-authority.逐字取自下载的视频转录。两套截然不同的打法 —— 一套建立在「共鸣症状 + 消解羞耻」上，另一套建立在「哲学重构 + 权威背书」上。
Across every ad, both advertisers use "support / optimize / enhance / restore" language — support energy and focus, support cellular energy, mental clarity — and never "treat / cure / disease." It is this functional-wellness vocabulary that lets Nadi sustain 61 active ads without falling foul of Meta's health-ad policy.在每一支广告里，两家都用「support / optimize / enhance / restore」的措辞 —— 支持能量与专注、支持细胞能量、思绪清晰 —— 而绝不用「治疗 / 治愈 / 疾病」。正是这套「功能养生」词汇，让 Nadi 能维持 61 支在投广告，而不触犯 Meta 的健康广告政策。
Reading every ad from both advertisers reveals four documented gaps — audiences and positions neither competitor currently serves.读遍两家诊所的每一支广告，浮现四个有据可查的空白 —— 两家竞品目前都未服务的受众与定位。
Longevity Clinic Asia produced zero Chinese-language video across 21 transcribed video ads. Nadi produces Chinese content but without a credentialed physician presenting on camera. The intersection — a Chinese-speaking registered physician building longevity authority through Chinese educational content — is a documented white space.Longevity Clinic Asia 在 21 支已转录的视频广告中，华文视频为零。Nadi 有华文内容，却没有具资历的医生出镜。两者的交集 —— 会说华语的注册医生用华文教育内容建立长寿医学权威 —— 是有据可查的空白。
Active longevity clinics concentrate in PJ, central KL and Mont Kiara. The USJ / Subang / Taipan corridor has no dedicated longevity clinic presence.活跃的长寿诊所集中在 PJ、吉隆坡市中心与满家乐。USJ / Subang / Taipan 走廊没有专门的长寿诊所。
The lowest public price for exosome-related treatment observed in the market is Nadi's P-SHOT at RM 2,800. No major advertiser publicly markets an entry-tier longevity product below that band.市场中观察到的外泌体相关疗程最低公开价，是 Nadi 的 P-SHOT RM 2,800。没有主要投广诊所公开营销低于此价位带的入门级长寿产品。
The "inside-out" narrative — one clinic serving a patient's desire to look younger while supporting cellular health as the mechanism — has not been systematically developed by either major competitor. The two verticals stay siloed.「由内而外」的叙事 —— 一家诊所同时服务患者「变美」的愿望，并以细胞健康作为机制 —— 两家主要竞品都没有系统化发展。两条业务线各自孤立。
Two advertisers, two clean niches, and four documented gaps between them. The Chinese-language physician lane, the suburban corridor, the accessible entry tier and the aesthetic-to-longevity bridge all remain open as of this snapshot.两家诊所、两个清晰的 niche，中间夹着四个有据可查的空白。华文医生赛道、郊区走廊、可及入门层与「从美到健」的桥梁，在此快照时都还空着。
The exosome sub-segment is a small but rapidly expanding slice of a very large longevity-medicine market. Figures below are shown as ranges, with each source's scope noted.外泌体细分，是一个庞大的长寿医学市场中，一个小但快速扩张的切片。以下数字以区间呈现，并标注各来源的口径。
Variance between sources reflects different scope definitions — some figures include pharmaceutical R&D and diagnostics (broader), others capture only clinical therapeutic applications (narrower). Grand View Research (USD 794M by 2030) is the most conservative and most cited. Broader longevity-market forecasts reach USD 46–67B by 2031–2035 (Mordor Intelligence 8.2% CAGR / SNS Insider 9.4% CAGR).各来源差异反映口径不同 —— 部分数字含药物研发与诊断（较广），部分仅含临床治疗应用（较窄）。Grand View Research（2030 年 USD 794M）最保守、被引用最多。更广义的长寿市场预测在 2031–2035 年达 USD 46–67B（Mordor Intelligence 8.2% CAGR / SNS Insider 9.4% CAGR）。
The category is moving from a transactional aesthetic-clinic model toward a protocol-based, repeat-architecture model — structurally analogous to a subscription: diagnostic onboarding, then recurring protocol consultations and treatments. Observed market tiers run from entry wellness IV, through core regenerative treatments, to premium annual protocols and flagship medical-tourism programmes.品类正从「交易型的医美诊所模式」转向「以方案为基础、有复购结构的模式」—— 结构上类似订阅：先做诊断入门，再进入周期性的方案咨询与治疗。观察到的市场层级，从入门养生 IV，到核心再生治疗，再到高端年度方案与旗舰医疗旅游项目。
The commercial category rests on three modalities. Each is described here as market positioning and regulatory status — not as clinical guidance.这个商业品类建立在三种技术之上。这里从市场定位与监管状态的角度描述 —— 不作临床指导。
Positioned by market leaders as "the next generation beyond PRP." Cell-free nanoparticles carrying regenerative signalling molecules; because they are biological messengers rather than live cells, market messaging frames them as more accessible than stem cell approaches. Regulatory status in Malaysia: grey zone.被市场领导者定位为「PRP 的下一代」。无细胞纳米颗粒，携带再生信号分子；因其是生物信使而非活细胞，市场讯息将其定位为比干细胞方案更可及。马来西亚监管状态：灰色地带。
Biological-age testing (epigenetic clocks, microbiome, metabolic panels) shifts the category from generic anti-ageing rhetoric to data-driven, individualised protocols. Commercially, this converts a one-off treatment into an ongoing, measurable protocol.生物年龄检测（表观遗传时钟、微生物组、代谢检测）让品类从笼统的抗衰老话术，转向数据驱动、个人化的方案。商业上，这把一次性治疗转化为持续、可衡量的方案。
Via IV or oral — the most commercially scalable entry-point treatment in the category. Regulatory risk is comparatively low (framed as a vitamin / supplement IV), consumer education is achievable, and the clinical experience is differentiatable.以 IV 或口服 —— 品类中商业上最可规模化的入门治疗。监管风险相对低（作为维生素／补充剂 IV），消费者教育可行，临床体验有差异化空间。
Malaysia's longevity clinic market comprises fewer than 20 meaningfully active commercial operators, best understood in three tiers.马来西亚长寿诊所市场由不到 20 家实质活跃的商业运营者构成，可从三个层级理解。
| Tier层级 | Description描述 | Representative operators代表运营者 |
|---|---|---|
| Tier 1 — Dedicated longevity第一梯队 — 专注长寿< 5 nationally全国不到 5 家 | Primary identity is longevity; full diagnostic protocols; IFM or equivalent certification; premium brand architecture以长寿为主要身份；完整诊断方案；IFM 或同等认证；高端品牌架构 | Longevity Clinic Asia (KL); Peak Protocol MY (KL)Longevity Clinic Asia（KL）；Peak Protocol MY（KL） |
| Tier 2 — Aesthetic × regenerative hybrid第二梯队 — 医美 × 再生 混合 | Built on an aesthetic foundation, added regenerative / longevity as a growth layer建立在医美基础上，加上再生 / 长寿作为增长层 | Nadi Clinic / Nadi Medi (PJ) |
| Tier 3 — Aesthetic + exosome add-ons第三梯队 — 医美 + 外泌体附加est. 30–50+ clinics估计 30–50+ 家 | Exosome facials / topicals / occasional IV marketed as an enhancement to aesthetics — KL / PJ / Subang外泌体护理 / 外用 / 偶尔 IV，作为医美的增值卖点 —— KL / PJ / Subang | High volume, low differentiation数量多、差异化低 |
| Clinic诊所 | Country国家 | Key differentiator核心差异 | Price tier价格档 |
|---|---|---|---|
| Human Longevity Inc | USA | Whole-genome sequencing + health-intelligence platform全基因组测序 + 健康情报平台 | $25k+/yr |
| Clinique La Prairie | Switzerland瑞士 | Century-old cellular-therapy heritage + Swiss luxury百年细胞疗法传承 + 瑞士奢华定位 | $30k–100k+/wk |
| SHA Wellness Clinic | Spain西班牙 | Integrative + gut microbiome + functional medicine整合 + 肠道微生物组 + 功能医学 | €5k+/wk |
| Longevity Clinic Asia | Malaysia马来西亚 | IFM-certified, Asia hub, international patientsIFM 认证、亚洲枢纽、国际患者 | Undisclosed (premium)不公开（高端） |
The global leaders compete not on a single treatment modality but on a comprehensive "health-intelligence platform" — diagnostics + personalised protocols + ongoing monitoring. That systems model, rather than a single-intervention clinic, is the long-term dominant design for the category.全球领导者的竞争，不在单一疗法，而在完整的「健康情报平台」—— 诊断 + 个人化方案 + 持续监测。这个系统化模式（而非单点治疗诊所）是品类长期的主导设计。
In Malaysia, what can be offered and advertised is defined less by demand than by three overlapping regulatory bodies and one recent framework change. This is the section that most separates informed operators from the rest.在马来西亚，能提供什么、能宣传什么，与其说由需求决定，不如说由三个重叠的监管机构与一次近期的框架变动界定。这一节，最能区分「懂行的运营者」与其他人。
Ministry of Health — policy authority for all healthcare services; publishes the Guideline for Stem Cell Research and Therapy.卫生部 —— 所有医疗服务的政策主管；发布《干细胞研究与治疗指南》。
National Pharmaceutical Regulatory Agency — regulates pharmaceutical and biological products; the primary authority for registering any cell-derived therapeutic.国家药剂监管局 —— 监管药品与生物制品；任何细胞来源治疗产品注册的主要机构。
Malaysian Medical Council — professional-standards body; its Ethical Guidelines govern medical advertising and clinical claims.马来西亚医药理事会 —— 专业标准机构；其《伦理指南》规范医疗广告与临床声明。
NPRA's Cell and Gene Therapy Products (CGTP) Guidelines, Second Edition, published September 2025, aligns Malaysia's cell-therapy pathway with WHO / FDA / EMA standards and opens a formal public-consultation process. Practical implication: injectable exosome products for IV or systemic use likely fall under advanced therapeutic products requiring formal NPRA registration. As of mid-2026, no exosome injectable product has received NPRA registration — clinics operate under physician discretion in an enforcement grey zone.NPRA 的《细胞与基因治疗产品（CGTP）指南》第二版，2025 年 9 月发布，使马来西亚的细胞治疗路径向 WHO / FDA / EMA 标准看齐，并开启正式的公众咨询程序。实务含义：用于 IV 或全身的注射型外泌体产品，很可能被归类为需正式向 NPRA 注册的先进治疗产品。截至 2026 年年中，尚无注射型外泌体产品取得 NPRA 注册 —— 诊所在执法灰区中，依医生裁量运作。
Malaysian law currently prohibits commercial promotion or provision of stem cell therapies outside Hematopoietic Stem Cell Transplantation for approved blood disorders (without formal MOH approval). This restriction does not currently apply to exosomes, which are not live cells. Longevity Clinic Asia explicitly positions exosome in advertising as "a powerful science-based alternative to stem cells, makes more accessible for everyone" — leveraging the regulatory accessibility of exosomes against the restrictions on stem cell commercialisation.马来西亚法律目前禁止在「用于已批准血液疾病的造血干细胞移植」以外，商业推广或提供干细胞疗法（无 MOH 正式批准的情况下）。此限制目前不适用于外泌体，因其非活细胞。Longevity Clinic Asia 在广告中明确将外泌体定位为「一个强大的、有科学依据的干细胞替代方案，让更多人可及」—— 借用外泌体的监管可及性，对比干细胞商业化所受的限制。
No guarantee of specific outcomes · no claims to treat, cure or prevent named conditions · no before-and-after implying therapeutic outcome · all claims substantiated. Enforced by both MMC and Meta's own ad policies. In practice, the sustained-ad advertisers — Nadi (61 ads), Longevity Clinic Asia (22 ads) — navigate compliance with functional-wellness language ("support cellular energy," "enhance vitality") rather than disease-treatment claims.不保证特定疗效 · 不宣称治疗、治愈或预防具名疾病 · 不用暗示疗效的前后对比图 · 所有声明须有依据。由 MMC 与 Meta 自身广告政策双重执行。实务上，持续投广的两家 —— Nadi（61 支）、Longevity Clinic Asia（22 支）—— 用「功能养生」语言（「支持细胞能量」「增强活力」）而非疾病治疗声明来维持合规。
| Jurisdiction司法管辖区 | Exosome status外泌体状态 | Practical implication实务含义 |
|---|---|---|
| United States (FDA)美国（FDA） | Regulated as biologics; IND required for most clinical use按生物制品监管；多数临床用途需 IND | Highly restricted commercial use商业使用高度受限 |
| European Union (EMA)欧盟（EMA） | Advanced Therapy Medicinal Products (ATMP) — certification required先进治疗药品（ATMP）—— 需认证 | Restricted commercial use商业使用受限 |
| Malaysia (NPRA)马来西亚（NPRA） | Grey zone — not formally classified under CGTP; physician discretion tolerated灰色地带 —— 未在 CGTP 下正式分类；容忍医生裁量 | Commercial use possible; regulatory risk exists商业使用可行；存在监管风险 |
| Thailand泰国 | More permissive framework; established medical-tourism destination框架更宽松；成熟的医疗旅游目的地 | Active market; attracts international patients市场活跃；吸引国际患者 |
| Singapore新加坡 | Strict — regulated as biologics; limited commercial use严格 —— 按生物制品监管；商业使用有限 | Minimal commercial market商业市场极小 |
Malaysia's regulatory posture is meaningfully more permissive than the US, EU and Singapore — comparable to Thailand — creating a genuine window as a longevity-medicine destination. That advantage is time-limited: NPRA's active consultation process signals that formalisation is coming.马来西亚的监管姿态，明显比美国、欧盟与新加坡更宽松 —— 与泰国相当 —— 为其作为长寿医学目的地创造了真实的窗口。但这个优势有时限：NPRA 正在进行的咨询程序，预示正式化即将到来。
Framed strictly as marketing positioning observed in competitor messaging — not clinical guidance. The strategic read stays macro; specific execution is out of scope for this report.严格以「竞品讯息中观察到的营销定位」呈现 —— 不作临床指导。战略判读仅停留在宏观层面；具体执行不在本报告范围内。
The market leader positions exosome as the affordable, regulatory-accessible entry to regenerative medicine — bypassing the restrictions and cost of stem cell approaches.市场领导者将外泌体定位为「进入再生医学」的可负担、监管可及入口 —— 绕开干细胞方案的限制与成本。
Sustained advertising presence correlates with "support / optimize / enhance" language rather than treatment claims — a marketing constraint that doubles as a filter on who can advertise durably.持续的广告存在，与「support / optimize / enhance」而非治疗承诺的语言相关 —— 这个营销约束，同时也是「谁能持续投广」的过滤器。
The Klang Valley longevity market has not consolidated; the regulatory grey zone is likely to narrow as NPRA formalises. Both conditions favour operators who establish clinical protocols, records and brand authority during the current window.巴生谷长寿市场尚未固化；随着 NPRA 正式化，监管灰区很可能收窄。这两个条件，都有利于在当前窗口内建立临床方案、记录与品牌权威的运营者。
Globally, the durable model is diagnostics + personalised protocol + ongoing monitoring — not a single-intervention clinic. Brand authority in this space compounds slowly, over years of content and clinical track record.从全球看，可持续的模式是诊断 + 个人化方案 + 持续监测 —— 而非单点治疗诊所。这个领域的品牌权威缓慢复利，需要数年的内容与临床记录积累。
Demand is rising, the field is unconsolidated, and Malaysia's regulatory posture is comparatively permissive today. The operators who will own this category are those who build compliant protocols, systems-level trust, and physician authority during a window that regulatory formalisation will eventually narrow.需求在上升，格局尚未固化，马来西亚今日的监管姿态相对宽松。将来占据这个品类的运营者，是那些在监管正式化最终收窄之前，建立合规方案、系统化信任与医生权威的人。